NASDAQ:ACIU AC Immune (ACIU) Stock Price, News & Analysis → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free ACIU Stock Alerts $3.41 -0.10 (-2.85%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$3.32▼$3.5150-Day Range$2.29▼$3.7852-Week Range$1.90▼$5.14Volume423,045 shsAverage Volume553,719 shsMarket Capitalization$337.25 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AC Immune alerts: Email Address AC Immune MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside369.2% Upside$16.00 Price TargetShort InterestHealthy0.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 22 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.74) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.49 out of 5 starsMedical Sector452nd out of 929 stocksPharmaceutical Preparations Industry213th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAC Immune has only been the subject of 1 research reports in the past 90 days.Read more about AC Immune's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.88% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AC Immune has recently decreased by 0.63%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACIU. Previous Next 2.6 News and Social Media Coverage News SentimentAC Immune has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for AC Immune this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by Institutions51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AC Immune's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.74) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AC Immune's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About AC Immune Stock (NASDAQ:ACIU)AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Read More ACIU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACIU Stock News HeadlinesMay 16 at 12:11 PM | markets.businessinsider.comBuy Rating Justified by Strategic Partnerships and Promising Pipeline in AC Immune SAMay 16 at 3:30 AM | americanbankingnews.comAnalysts Offer Predictions for AC Immune SA's FY2025 Earnings (NASDAQ:ACIU)May 15 at 6:31 PM | markets.businessinsider.comBuy Rating Affirmed: AC Immune’s Promising Alzheimer’s Vaccine and Strategic Takeda PartnershipMay 14 at 5:21 AM | ft.comTakeda Pharmaceuticals reaches $2bn deal to develop Alzheimer’s vaccineMay 13, 2024 | msn.comAlzheimer’s vaccine licensing deal boosts AC ImmuneMay 13, 2024 | finance.yahoo.comSector Update: Health Care Stocks Mixed Late AfternoonMay 13, 2024 | investorplace.comACIU Stock Earnings: AC Immune Misses EPS for Q1 2024May 13, 2024 | investorplace.comWhy Is AC Immune (ACIU) Stock Up 45% Today?May 13, 2024 | marketwatch.comAC Immunity Shares Soar on Exclusive License Deal with TakedaMay 13, 2024 | sfgate.comAC Immune: Q1 Earnings SnapshotMay 13, 2024 | finance.yahoo.comTakeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment CandidateMay 13, 2024 | globenewswire.comAC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 13, 2024 | globenewswire.comAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseMay 13, 2024 | businesswire.comAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's DiseaseMay 9, 2024 | americanbankingnews.comAC Immune (NASDAQ:ACIU) Upgraded to "Hold" at StockNews.comApril 27, 2024 | money.usnews.comAC Immune SAApril 18, 2024 | finance.yahoo.comAC Immune SA (ACIU)April 11, 2024 | finance.yahoo.comWe Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business GrowthMarch 20, 2024 | wsj.comAC Immune S.A.March 15, 2024 | markets.businessinsider.comBuy Rating for AC Immune SA on Promising Alzheimer’s Vaccine Trial Design and Potential Accelerated ApprovalMarch 15, 2024 | finance.yahoo.comFurther weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58%March 14, 2024 | finance.yahoo.comACIU Mar 2024 2.500 putMarch 14, 2024 | globenewswire.comAC Immune Reports Full Year 2023 Financial Results and Provides a Corporate UpdateFebruary 22, 2024 | finanznachrichten.deAC Immune SA: AC Immune Announces Upcoming Presentations at AD/PD 2024February 22, 2024 | finance.yahoo.comAC Immune Announces Upcoming Presentations at AD/PD™ 2024See More Headlines Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/16/2024Next Earnings (Estimated)8/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACIU CUSIPN/A CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees133Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+369.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,410,000.00 Net MarginsN/A Pretax Margin-366.34% Return on Equity-38.84% Return on Assets-34.30% Debt Debt-to-Equity RatioN/A Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$16.48 million Price / Sales20.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.61Miscellaneous Outstanding Shares98,900,000Free Float94,350,000Market Cap$337.25 million OptionableOptionable Beta1.05 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Andrea Pfeifer Ph.D. (Age 67)Co-Founder, CEO & Director Comp: $1.09MMr. Christopher Roberts (Age 34)CFO & VP of Finance Mr. Piergiorgio Donati (Age 53)Chief Technical Operations Officer Mr. Jean-Fabien Monin (Age 53)Chief Administrative Officer Mr. Howard Donovan (Age 48)Chief HR Officer Ms. Madiha Derouazi (Age 51)Chief Scientific Officer Dr. Gary Anthony Waanders Ph.D. (Age 60)Senior VP of Investor Relations & Corporate Communications Mr. Alexandre Caratsch (Age 58)General Counsel Mr. Julian SnowVP of U.S. Finance & Corporate DevelopmentDr. David T. HickmanHead of AD - SMEMore ExecutivesKey CompetitorsRevance TherapeuticsNASDAQ:RVNCNanobiotixNASDAQ:NBTXPrecigenNASDAQ:PGENFibroBiologicsNASDAQ:FBLGAmarinNASDAQ:AMRNView All CompetitorsInstitutional OwnershipRedmile Group LLCBought 7,031 shares on 5/16/2024Ownership: 2.029%Lazard Asset Management LLCBought 10,260 shares on 5/15/2024Ownership: 0.010%Platinum Investment Management Ltd.Sold 420,559 shares on 5/14/2024Ownership: 1.107%BNP Paribas Financial MarketsBought 8,423 shares on 5/1/2024Ownership: 0.011%China Universal Asset Management Co. Ltd.Bought 9,334 shares on 4/29/2024Ownership: 0.019%View All Institutional Transactions ACIU Stock Analysis - Frequently Asked Questions Should I buy or sell AC Immune stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACIU shares. View ACIU analyst ratings or view top-rated stocks. What is AC Immune's stock price target for 2024? 1 equities research analysts have issued 12-month price objectives for AC Immune's shares. Their ACIU share price targets range from $16.00 to $16.00. On average, they expect the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 369.2% from the stock's current price. View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts. How have ACIU shares performed in 2024? AC Immune's stock was trading at $5.00 on January 1st, 2024. Since then, ACIU stock has decreased by 31.8% and is now trading at $3.41. View the best growth stocks for 2024 here. When is AC Immune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 2nd 2024. View our ACIU earnings forecast. How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $16.71 million for the quarter, compared to the consensus estimate of $16.36 million. What is Andrea Pfeifer's approval rating as AC Immune's CEO? 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV). When did AC Immune IPO? AC Immune (ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO. Who are AC Immune's major shareholders? AC Immune's stock is owned by a variety of retail and institutional investors. Top institutional investors include Redmile Group LLC (2.03%), Platinum Investment Management Ltd. (1.11%), China Universal Asset Management Co. Ltd. (0.02%), BNP Paribas Financial Markets (0.01%), Lazard Asset Management LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACIU) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsHow Biden has already won 2024Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe 1,000X Crypto PlaybookTrue Market InsidersWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
